Bruce Williams, Interim Chairman

Bruce Williams has significant operational experience in the biopharmaceutical industry and has held senior leadership positions at both large pharmaceutical firms and start-up biotechs. He served as Senior Vice President, Global Business Management at Enzon Pharmaceuticals, where he led the company’s commercial functions. Prior to that, he was Senior Vice President, Sales & Marketing at Genta Incorporated, where he built and led the sales and marketing function and negotiated a licensing and co-development/co-marketing agreement with Aventis for the company’s lead product. He was previously Vice President of Sales & Marketing at Celgene Corporation, where he built the company’s commercial and distribution infrastructure to support the launch of its first product, Thalomid (thalidomide). Earlier in his career, Mr. Williams was Executive Director, Marketing at Ortho Biotech (subsidiary of Johnson & Johnson), where he led the marketing of Procrit (epoetin alfa) from pre-approval through its first year of $1 billion in sales. In addition to Motif Bio, Mr. Williams currently serves on the board of Afaxys Incorporated. He also serves on the Board of Trustees of Rutgers Preparatory School and is Treasurer and Trustee of the Independent School Chair Association. He holds an MBA from Columbia University and a Bachelor of Arts degree in biology from Syracuse University.

Graham Lumsden, Chief Executive Officer, Director

Graham Lumsden, Chief Executive Officer of Motif, is responsible for all aspects of the strategy, management, and operations of the Company. Prior to joining Motif, Mr. Lumsden was Worldwide Business Leader, Contraceptives and Osteoporosis at Merck & Co., Inc. where he previously held other international senior leadership roles as well as senior marketing positions. Mr. Lumsden has a proven record of success leading change and delivering results at Worldwide Vice President level including cross-functional team leadership, new product launches, pre-clinical / clinical development, regulatory strategy, IP strategy / litigation, and domestic / international sales and marketing. Mr. Lumsden is a member of the Royal College of Veterinary Surgeons (MRCVS), holds a masters from the Chartered Institute of Marketing (MCIM), and is a dual citizen of the U.S. and UK.

Craig T. Albanese, M.D., M.B.A., Non-Executive Director

Craig T. Albanese, M.D., M.B.A., is the Senior Vice President and Chief Operating Officer, New York-Presbyterian/Morgan Stanley Children’s Hospital and Sloane Hospital for Women.

Dr. Albanese is responsible for overseeing all operations and managing the strategic direction of the children’s and women’s hospital. He has spent the last 15 years in various leadership positions in healthcare.  Prior to his position at New York Presbyterian (NYP), he spent 14 years at Stanford Children’s Health, most recently serving as the Vice President of Quality and Performance Improvement. He also served as the John A. and Cynthia Fry Gunn Director of Pediatric Surgical Services at Lucile Packard Children’s Hospital, and was a Professor of Surgery, Pediatrics, and Obstetrics and Gynecology at Stanford University Medical Center.

Prior to this, Dr. Albanese held faculty appointments and leadership roles at the Children’s Hospital of Pittsburgh and the University of California, San Francisco. After receiving his medical degree from SUNY Health Science Center in Brooklyn, Dr. Albanese was a resident and chief resident in general surgery at Mount Sinai Medical Center. He then completed pediatric general surgery and critical care research fellowships at Children’s Hospital of Pittsburgh.

Dr. Albanese also holds a Master’s in Business Administration from the Leavey School of Business at Santa Clara University. He has published more than 160 peer reviewed articles, was an NIH-funded investigator, and the program director for Stanford’s pediatric general surgery fellowship. An expert in management and improvement science and operations, he published a best-selling book on improvement science in health care entitled, “Advanced Lean in Healthcare. His recent work at NYP has been aimed at implementing a daily management system across NYP’s 6 hospitals. Dr. Albanese is also the executive sponsor for Graduate Medical Education at NYP, the nation’s largest single site training program.

Mary Lake Polan, M.D, Ph.D, MPH, Non-Executive Director

Mary Lake Polan, M.D., Ph.D., M.P.H., is a Clinical Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine. Dr. Polan specializes in reproductive endocrinology and infertility and hormonal issues related to gynecology patients and menopause. She received her bachelor’s degree from Connecticut College and her Ph.D. in Molecular Biophysics and Biochemistry and M.D. from Yale University and completed her residency and Reproductive Endocrine Fellowship in the Department of Obstetrics and Gynecology at the Yale University School of Medicine. Dr. Polan received her M.P.H. (Maternal and Child Health Programme) from the University of California, Berkeley.

Dr. Polan served on the board of Wyeth Pharmaceuticals prior to its acquisition by Pfizer and currently serves on the board of Quidel Corp, San Diego, CA and on the boards of several privately held life sciences companies. She chairs an SAB in Women’s Health for the Proctor and Gamble Company and several other advisory boards of private life sciences companies. She is also a Managing Director of Golden Seeds, an angel investing group which invests in women led companies.

Zaki Hosny, Non-Executive Director

Zaki Hosny is an independent consultant to life sciences companies. Mr. Hosny spent most of his career at Merck & Co in marketing and general management positions around the globe, including management responsibility for the company’s business in major markets in Europe. Mr. Hosny also held senior marketing roles with worldwide responsibility for cardiovascular and other franchises, and was closely involved in the clinical development of some of the company’s major products.

Mr. Hosny was Chief Executive Officer of Motif from 2006-13, and Deputy Chairman of its Board of Directors. Mr. Hosny is currently a Senior Advisor to the Albright Stonebridge Group, a strategic consultancy firm based in Washington, D.C. Mr. Hosny is also a consultant to Harel Consulting of New Jersey and Mettle Consulting of the UK. Mr. Hosny is based in Princeton, NJ and is a graduate of Cambridge University with an MA in history and law.

Charlotta Ginman, Non-Executive Director

Charlotta qualified as a Chartered Accountant before spending a career in investment banking and commercial organisations, principally in technology-related businesses. Charlotta began her career at Ernst & Young in 1989, and was then appointed to a series of senior roles in investment banking with UBS, Deutsche Bank and JP Morgan both in London and Singapore, where she gained considerable M&A transactional experience.

Charlotta has also held senior roles within Nokia Corporation, including acting as Chief Financial Officer of its luxury mobile phone division Vertu Corporation Limited. Charlotta is an experienced NED, currently sitting on the Boards of Pacific Assets Trust plc, Polar Capital Technology Trust plc, Unicorn AIM VCT plc, Keywords Studios plc and Consort Medical plc.

Jonathan E. Gold, Interim Chief Financial Officer

Mr. Gold has a history of senior financial positions and is currently Managing Director of JEG Capital Partners LLC, a family office and asset manager. He previously was a portfolio manager for the Federated Kaufmann Funds. Prior to that, Mr. Gold was a venture capitalist and was active in financing and building life sciences and technology companies. Mr. Gold received his B.S. and MBA in Finance from New York University’s Stern School of Business.